<DOC>
	<DOCNO>NCT02547714</DOCNO>
	<brief_summary>The purpose study assess efficacy safety secukinumab Week 16 base psoriasis area severity index ( PASI ) 75 subject inadequate response cyclosporine A .</brief_summary>
	<brief_title>Open-label Study Subcutaneous Secukinumab Evaluate Efficacy Safety Patients With Plaque Psoriasis Who Had Inadequate Response Cyclosporine A</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<criteria>Inclusion criterion : Plaque psoriasis diagnose least 6 month baseline Treated cyclosporine A least 12 week prior baseline Currently treat cyclosporine A baseline psoriasis primary secondary inadequate response define baseline : PASI score 10 great IGA mod 2011 score 2 great ( base scale 0 4 ) Forms psoriasis plaque ( e.g. , pustular , erythrodermic guttate psoriasis ) . Druginduced psoriasis ( i.e. , new onset current exacerbation betablockers , calcium channel blocker lithium ) . Patients discontinue cyclosporine A treatment due side effect like renal impairment ( serum creatinine exceed 176.8 Î¼mol/L [ 2.0 mg/dL ] ) hypertension screening . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>cyclosporine A</keyword>
</DOC>